Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oric Pharmaceuticals Inc.

5.10
-0.0900-1.73%
Post-market: 5.100.00000.00%17:05 EDT
Volume:362.90K
Turnover:1.85M
Market Cap:362.24M
PE:-2.78
High:5.17
Open:5.08
Low:4.91
Close:5.19
Loading ...

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Apr

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Apr

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
02 Apr

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
01 Apr

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire
·
26 Mar

Oric Pharmaceuticals Expands Equity Incentive Plan for Growth

TIPRANKS
·
15 Mar

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
08 Mar

ORIC Pharmaceuticals Reports Progress in Cancer Trials

TIPRANKS
·
06 Mar

Oric Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
27 Feb

Oric Pharmaceuticals Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Feb

Positive Outlook for Oric Pharmaceuticals: Buy Rating Affirmed on Promising ORIC-944 Updates and Strategic Refocus

TIPRANKS
·
26 Feb

Oric Pharmaceuticals (ORIC) Gets a Buy from Oppenheimer

TIPRANKS
·
26 Feb

Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114

TIPRANKS
·
26 Feb

Oric Pharmaceuticals Inc: Projected Cash Runway Extended Into 2027 Under Refined Operating Plan

THOMSON REUTERS
·
26 Feb

Stock Track | ORIC Pharmaceuticals Soars 7.21% on Focused Registrational Plans and Extended Cash Runway

Stock Track
·
26 Feb

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

GlobeNewswire
·
26 Feb

Oric Pharmaceuticals Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Feb

Positive Growth Outlook for Oric Pharmaceuticals Driven by Clinical Catalysts and Financial Stability

TIPRANKS
·
21 Feb

Stock Track | ORIC Pharmaceuticals Soars 9.17% Pre-Market as Jefferies Raises Price Target

Stock Track
·
19 Feb

U.S. RESEARCH ROUNDUP-Axsome Therapeutics, Penumbra, Republic Services

Reuters
·
19 Feb